Juno Therapeutics, Inc.

SEC insider activity covers quarterly filings through June 30, 2026. Later filings are not included. Reported roles do not establish current employment or current holdings. SEC filing documents, sections and filing-text search cover filings dated January 1, 2000 onward. Earlier filings are deferred until after launch.

organization

SEC Insider

$2.04B

436 transactions

Summary

Juno Therapeutics, Inc. is an organization.

Recent Insider Transactions

As filed, including amendments; not net cash flow or current holdings. Joint reports count once. Totals cover known values only.

Buys: $34.4MSales: $707.5M27 insiders

Date	Insider	Type	Value
2018-03-05	Barron Hal	U	$8.7M
2018-03-05	Barron Hal	D	$6.0M
2018-03-05	Barron Hal	D	$765K
2018-03-05	Barron Hal	D	$535K
2018-03-05	Barron Hal	D	$329K
2018-03-05	Barron Hal	D	$324K
2018-03-05	AGARWAL SUNIL(President of R & D)	D	—
2018-03-05	AGARWAL SUNIL(President of R & D)	D	—
2018-03-05	AGARWAL SUNIL(President of R & D)	D	—
2018-03-05	AGARWAL SUNIL(President of R & D)	D	—
2018-03-05	Azelby Robert(EVP & Chief Commercial Officer)	D	—
2018-03-05	Azelby Robert(EVP & Chief Commercial Officer)	D	—
2018-03-05	Azelby Robert(EVP & Chief Commercial Officer)	D	—
2018-03-05	Azelby Robert(EVP & Chief Commercial Officer)	D	—
2018-03-05	Azelby Robert(EVP & Chief Commercial Officer)	D	—
2018-03-05	Azelby Robert(EVP & Chief Commercial Officer)	D	—
2018-03-05	Azelby Robert(EVP & Chief Commercial Officer)	D	—
2018-03-05	Bishop Hans Edgar(CEO & President)	D	—
2018-03-05	Bishop Hans Edgar(CEO & President)	D	—
2018-03-05	Bishop Hans Edgar(CEO & President)	D	—

SEC filings: SEC EDGAR

Activity data: SEC EDGAR

Juno Therapeutics, Inc. — Contributions, Lobbying & Contracts | Poliscope